SCHEMBL18005255

SCHEMBL18005255

CC(C)c1oc(-c2ccc(F)c(Cl)c2)nc1-c1nn[nH]c1C#N

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPK14 Q16539 2/20 0.36
ALOX15 P16050 2/20 0.35
GRM5 P41594 1/20 0.35
MET P08581 2/20 0.34
TRPV3 Q8NET8 1/20 0.34
TGFBR1 P36897 5/20 0.33
TGFBR2 P37173 2/20 0.33
KDM4E B2RXH2 1/20 0.32
ALDH1A1 P00352 1/20 0.32
GAA P10253 1/20 0.32
HPGD P15428 1/20 0.32
HSD17B10 Q99714 1/20 0.32
ADORA2A P29274 1/20 0.32
ADORA1 P30542 1/20 0.32
NOTUM Q6P988 1/20 0.32
SUCNR1 Q9BXA5 1/20 0.32
ESR1 P03372 1/20 0.31
ESR2 Q92731 1/20 0.31
PGR P06401 1/20 0.31
PGGT1B P53609 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18005386 0.90 ALOX15 (0.45) MAPK14ALOX15KDM4EALDH1A1HPGD
SCHEMBL18005405 0.90 ESR1 (0.35) MAPK14ALOX15METTRPV3KDM4E
SCHEMBL18005334 0.87 ALOX15 (0.37) ALOX15GRM5METTGFBR1TGFBR2
SCHEMBL18005330 0.87 MET (0.35) MAPK14ALOX15GRM5METTRPV3
SCHEMBL16399661 0.87 KDM4E (0.41) ALOX15KDM4EALDH1A1GAAHPGD
SCHEMBL18005399 0.85 ALOX15 (0.35) ALOX15GRM5METTGFBR1TGFBR2
SCHEMBL16399478 0.85 KDM4E (0.45) MAPK14ALOX15KDM4EALDH1A1GAA
SCHEMBL18005495 0.84 ALOX15 (0.35) ALOX15GRM5METTGFBR1TGFBR2
SCHEMBL18005324 0.84 ALOX15 (0.34) ALOX15GRM5METTGFBR1TGFBR2
SCHEMBL18005500 0.82 GRM5 (0.36) ALOX15GRM5METTGFBR1TGFBR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4219477-A1 CYANOTRIAZOLE COMPOUNDS Otsuka Pharmaceutical Co., Ltd. (JP) 2023-08-02 EP disclosed
US-10626095-B2 Cyanotriazole compounds OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2020-04-21 US disclosed
US-20160229816-A1 CYANOTRIAZOLE COMPOUNDS OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2016-08-11 US disclosed
US-20160229816-A1 CYANOTRIAZOLE COMPOUNDS OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2016-08-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10626095-B2 Cyanotriazole compounds CS, PC, ACAT1 MAPK14 663/4885ALOX15 2623/4885GRM5 1425/4885
US-20160229816-A1 CYANOTRIAZOLE COMPOUNDS CS, PC, ACAT1 MAPK14 663/4885ALOX15 2623/4885GRM5 1425/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.